DeLong Mark Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Feb 13, 2024
Insider Transaction Report
Form 4
DeLong Mark Jeffrey
Chief Business & Strat Officer
Transactions
- Sale
Common Stock
2024-02-12$67.77/sh−597$40,457→ 64,606 total
Footnotes (1)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on 02/09/2024.